|ACS Career News|
|Sept. 23, 2010|
Interview and Network — without travel costs or hassles
Register now for the ACS Virtual Career Fair
9 to 6 p.m. EST Nov. 2 to 3
Using our new interactive platform, you'll be able to interview via text or video chat, attend six webinars and network with professionals worldwide — from the convenience of your own desktop. Don't miss the two keynotes with Rudy Baum, editor-in-chief of C&EN, and Richard N. Bolles, the acclaimed author of What Color is Your Parachute and The Job Hunter's Survival Guide.
Job seekers: learn more | register
Employers: learn more | register
This is a free ACS Careers event co-sponsored by Informex and C&EN. ACS membership is not required to participate.More
Global Patent Protection and International Business Strategies
American Chemical Society
Time/date: 2 to 3 p.m. ET Sept. 30.
Guest speaker: Dr. Michael Brodowski, attorney at law, K&L Gates.
Science and business opportunities are no longer confined to the United States. Do you know how to protect your research and inventions in this global market?
Technical and Leadership Skills to Advance Your Sustainability Toolkit
American Chemical Society
Time/date: 1 to 2:30 p.m. ET Oct. 12. There will be a 1-hour presentation followed by a 30-minute Q&A.
Guest speakers: Randi Schoenfelder, managing partner, Theodolite Human Capital, LLC; Ann Lee-Jeffs, manager of product stewardship, Johnson & Johnson.
Advance your career as more companies move to a sustainable business model
ACS Careers in partnership with Theodolite Human Capital has conducted a comprehensive study to find out what organizations will need to support their sustainability strategies, and what ACS members will need to retool and advance their careers in the new green economy.
Acing tricky questions
The Wall Street Journal
On her second round of interviews for an editorial job in Chicago, Jess Wangsness was asked: If you could be a giraffe without a neck or an elephant without a trunk, which would you choose and why? "Even though none of it had anything to do with the job, we had a fairly animated conversation about elephant behavior," Wangsness says. She didn't get the job but still wonders about the question. "Perhaps employers simply like to gauge just how interesting their candidates really are?" she says. Regardless of how offbeat some interview questions may sound, most employers have their own hidden reasons for asking them.More
CEO: $1B funding for Rochester, Minn., biotech park close to reality
After weathering delays and doubts from critics, biotech guru G. Steven Burrill said that he's close to securing $1 billion to support a major biobusiness park he envisions on a rural tract north of Rochester, Minn. The investment would be a huge step toward reality for the project, dubbed Elk Run. It began with aspirations to bring biotech companies to a site near the famed Mayo Clinic. But the project has been slowed by a rough economy that made it tougher to secure funding to develop the site and help fund the companies that would operate there.More
Despite cuts, Genzyme hiring in Massachusetts
The Boston Globe
Even as it moves to shed 1,000 jobs by the end of next year, Genzyme Corp. is accelerating the hiring of manufacturing and quality control workers in Massachusetts, where it recently built a plant in Framingham and expanded its Allston Landing site. Overall, the Cambridge biotechnology company plans to add 500 to 600 production jobs in the state between July 1 of this year and the end of 2011, a senior executive said.More
Pfizer sees turnaround for poorly performing labs
The public has good reason to look beyond Pfizer Inc's disappointing track record in developing new medicines, the drugmaker's research chief told investors. Mikael Dolsten, speaking at the Morgan Stanley Global Healthcare Conference in New York, said the company would have preferred more new drugs to have come out of its laboratories in recent years. Few big-selling medicines have emerged from Pfizer's labs since its Viagra anti-impotence pill was introduced in 1998, despite the company's unmatched research budget.More
Do rich markets lure biotechs away from low-cost remedies?
A pair of Canadian researchers has taken a close look at 78 small biotech companies operating in India, Brazil, China and South Africa and found that many are pursuing a host of new drugs and vaccines that would be affordable in the developing world. But there's a caveat: Many of these developers may be deflected from their mission if they're hijacked by companies more interested in treating the diseases that afflict the affluent in industrial countries.More